Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;26(4):213-224.
doi: 10.11005/jbm.2019.26.4.213. Epub 2019 Nov 30.

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

So Young Park  1 , Seong Hee Ahn  2 , Jun-Il Yoo  3 , Youn-Jee Chung  4 , Yun Kyung Jeon  5 , Byung-Ho Yoon  6 , Ha Young Kim  7 , Seung Hun Lee  8 , Jehoon Lee  9 , Seongbin Hong  2
Affiliations
Review

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

So Young Park et al. J Bone Metab. 2019 Nov.

Abstract

Current evidences continue to support the clinical application of bone turnover markers (BTMs) in the management of postmenopausal osteoporosis. The limitations of bone mineral density measured by dual energy X-ray absorptiomet especially emphasize the beneficial roles of BTMs, such as serum C-terminal telopeptide of type I collagen and serum procollagen type I N-propeptide, as monitoring tools to assess the responses to treatment. Therefore, the proper application and assessment of BTM in clinical practice is very important. However, their use in Korea is still insufficient. Therefore, the BTM committee has set up by the Korean Society for Bone and Mineral Research have been constituted and provided a position statement which will suggest on the clinical application of BTM for the management of postmenopausal osteoporosis in Korea.

Keywords: Bone remodeling; Osteoporosis; Republic of Korea.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. The algorithm of bone turnover marker use in osteoporosis treatment. PINP, propeptide of type I collagen; BSALP, bone specific alkaline phosphatase; CTX-1, C-terminal telopeptide of type I collagen; NTX-1, N-terminal telopeptide of collagen type I; DPD, deoxypyridinoline; PYD, pyridinoline; BP, bisphosphonate; SERM, selective estrogen receptor modulator; LSC, least significant changes.
See this image and copyright information in PMC

References

    1. Peck WA, Burckhardt P, Christiansen C, et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646–650. - PubMed
    1. Weinstein RS. True strength. J Bone Miner Res. 2000;15:621–625. - PubMed
    1. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007;10:102–110. - PubMed
    1. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121–145. - PMC - PubMed
    1. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–1538. - PubMed